Furthermore, ESR2 was identified as the transcriptional target of TFAP2A by bioinformatics analysis and ChIP, and the combination of the ESR2 inhibitor PHTPP and osimertinib had a synergistic effect on NSCLC with a high level of TFAP2A. This evidence concerns the gene ESR2 and non-small cell lung carcinoma.